TELO Telomir Pharmaceuticals Inc

Price (delayed)

$1.27

Market cap

$87.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.29

Enterprise value

$81.99M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 29
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 7

We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for ...

Highlights
The quick ratio has grown by 32% from the previous quarter
Telomir Pharmaceuticals's EPS has increased by 31% YoY and by 12% QoQ
Telomir Pharmaceuticals's equity has decreased by 16% QoQ

Key stats

What are the main financial stats of TELO

TELO stock price

How has the Telomir Pharmaceuticals stock price performed over time
Intraday
3.25%
1 week
-0.78%
1 month
-3.79%
1 year
-39.81%
YTD
-4.51%
QTD
-2.31%

Financial performance

How have Telomir Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.39M
Net income
-$9.22M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 26% YoY and by 11% QoQ
TELO's operating income is up by 25% year-on-year and by 11% since the previous quarter

Price vs fundamentals

How does TELO's price correlate with its fundamentals

Growth

What is Telomir Pharmaceuticals's growth rate over time

Valuation

What is Telomir Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Telomir Pharmaceuticals's EPS has increased by 31% YoY and by 12% QoQ
The price to book (P/B) is 66% less than the last 4 quarters average of 25.1
Telomir Pharmaceuticals's equity has decreased by 16% QoQ

Efficiency

How efficient is Telomir Pharmaceuticals business performance
The ROE has soared by 90% YoY and by 36% from the previous quarter
The return on assets has surged by 83% year-on-year and by 33% since the previous quarter

Dividends

What is TELO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TELO.

Financial health

How did Telomir Pharmaceuticals financials performed over time
TELO's total liabilities is down by 42% since the previous quarter but it is up by 27% year-on-year
TELO's current ratio is up by 36% from the previous quarter
Telomir Pharmaceuticals's debt is 96% less than its equity
Telomir Pharmaceuticals's equity has decreased by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.